COMMUNIQUÉS West-GlobeNewswire

ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026
19/05/2026
EINDHOVEN, The Netherlands, May 19, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence [...]
Khondrion Announces First Patient Dosed in Phase II Study Targeting Debilitating Post-COVID Fatigue
19/05/2026
SON4PEM trial advances development of sonlicromanol, aiming to address chronic fatigue in Post-COVID patients with post-exertional malaise NIJMEGEN, The Netherlands, May 19, 2026 (GLOBE NEWSWIRE) -- Khondrion today [...]
Unaudited Preliminary Results for the Year Ended December 31, 2025
19/05/2026
LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery [...]
Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering
19/05/2026
Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with the potential of up to approximately $32 million in the event the warrants offered in this offering are exercised, to [...]
Fangzhou Ranked among 2025 Guangzhou AI Innovation “Most Promising Enterprises” for AI‑Powered Chronic Disease Services
19/05/2026
GUANGZHOU, China, May 19, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, was invited to attend the 2026 Guangzhou [...]
Rapid Nutrition Advances Finalization of Australian Flagship Initiative
19/05/2026
LONDON, May 19, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD ), a global HealthTech company focused on evidence-based nutrition brands, is pleased to provide an update regarding its Australian [...]
Pennant Group to Participate in the 2026 RBC Global Healthcare Conference
19/05/2026
EAGLE, Idaho, May 18, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it will [...]
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
18/05/2026
– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease – RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, [...]
Pennant Announces an Acquisition of Senior Living Community in Arizona
18/05/2026
EAGLE, Idaho, May 18, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announces the [...]
ATI Advisory Launches Public Dashboard on C-SNPs and Eligible Populations
18/05/2026
New resource offers insight into the characteristics of Medicare beneficiaries enrolling in C-SNP and eligible enrollees in other plan types, including dual eligibles and beneficiaries with frailty, as MA plans face [...]
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
18/05/2026
IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment. Maximum dose reached with no dose-limiting toxicities observed. TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT, which is [...]
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
18/05/2026
CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in [...]
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
18/05/2026
Data reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with monthly dosing On [...]
Precision Optics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
18/05/2026
LITTLETON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/ [...]
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/05/2026
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on May 11, 2026, [...]
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/05/2026
WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
Certara to Participate in Upcoming Investor Conferences
18/05/2026
RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor [...]
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
18/05/2026
BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system [...]
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
18/05/2026
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD Data from the head-to-head study show efdoralprin alfa normalized [...]

Pages